Endoscopy

Ambu Awarded for Excellence in Product Design

Thursday, April 15, 2021 - 1:30pm

b'The winners of the \xe2\x80\x98Red Dot Award: Product Design 2021\xe2\x80\x99 have been announced, and Ambu is a double winner with awards for the company\xe2\x80\x99s cystoscope and duodenoscope \xe2\x80\x93 both single-use endoscopes.\nThis press release features multimedia.

Key Points: 
  • b'The winners of the \xe2\x80\x98Red Dot Award: Product Design 2021\xe2\x80\x99 have been announced, and Ambu is a double winner with awards for the company\xe2\x80\x99s cystoscope and duodenoscope \xe2\x80\x93 both single-use endoscopes.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210415005558/en/\nPictured left is Ambu\xc2\xae aScope\xe2\x84\xa2 Duodeno and right, Ambu\xc2\xae aScope\xe2\x84\xa2 4 Cysto, both winners of Red Dot design awards 2021.
  • With more than 18,000 entries, the Red Dot Award is one of the world\xe2\x80\x99s largest design competitions.
  • Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,000 people in Europe, North America and the Asia Pacific.

Insights on the Veterinary Endoscopy Global Market to 2026 - Players Include Medtronic, Olympus and Steris Among Others - ResearchAndMarkets.com

Monday, April 12, 2021 - 12:01pm

The most common flexible endoscopic procedures performed both in specialty and general practices are upper and lower GI endoscopy, for direct examination and biopsy of selected areas of the GI tract.

Key Points: 
  • The most common flexible endoscopic procedures performed both in specialty and general practices are upper and lower GI endoscopy, for direct examination and biopsy of selected areas of the GI tract.
  • Companies such as STERIS have experience in Endo-i Veterinary Endoscope repairs, which is one of the significant investments for veterinary practices.
  • Also, the growing pet population along with increasing spending on pet care is fueling the market's growth.
  • Hence, owing to the aforementioned factors, the studied market is expected to witness significant growth in North America over the forecast period.\n"

Consolidate Your Health Records with Therap's "Life Records for Families and Individuals" Electronic Health Record (EHR) System

Tuesday, April 13, 2021 - 6:00pm

b"WATERBURY, Conn., April 13, 2021 /PRNewswire/ -- As medical practices, clinics, and hospitals become more specialized it can be difficult to see the same doctor on a regular basis and even harder to manage your medical records.

Key Points: 
  • b"WATERBURY, Conn., April 13, 2021 /PRNewswire/ -- As medical practices, clinics, and hospitals become more specialized it can be difficult to see the same doctor on a regular basis and even harder to manage your medical records.
  • A clinic may hand you a record of a colonoscopy, electrocardiogram, or lab work as you walk out the door but where do you keep it and how big a folder do you lug to your next appointment.
  • The power and sophistication of Therap's Industry leading EHR is now available and affordable for individuals and families to maintain your medical history and, if necessary, the medical histories of your family in an easily accessible web based EHR system.\nTherap began developing and marketing its EHR in 2003 for human services organizations.
  • Therap's system is web based, inexpensive, transparent, and full featured.

Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

Monday, April 12, 2021 - 6:00am

The device is the first of its kind to obtain the FDA approval through the De Novo application.

Key Points: 
  • The device is the first of its kind to obtain the FDA approval through the De Novo application.
  • ), where detection rates improved very significantly with GI Genius technology versus standard colonoscopy, regardless of skill level or endoscope used.
  • The first ever approval of an artificial intelligence device for lesion detection in colonoscopies further strengthens Cosmo\'s commitment to fight colorectal cancer.
  • We are extremely pleased and very optimistic about the impact the GI Genius intelligent endoscopy module will have on the US patient population undergoing colonoscopy.

Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

Monday, April 12, 2021 - 6:00am

The device is the first of its kind to obtain the FDA approval through the De Novo application.

Key Points: 
  • The device is the first of its kind to obtain the FDA approval through the De Novo application.
  • ), where detection rates improved very significantly with GI Genius technology versus standard colonoscopy, regardless of skill level or endoscope used.
  • The first ever approval of an artificial intelligence device for lesion detection in colonoscopies further strengthens Cosmo\'s commitment to fight colorectal cancer.
  • We are extremely pleased and very optimistic about the impact the GI Genius intelligent endoscopy module will have on the US patient population undergoing colonoscopy.

Laparoscopic Instruments Market worth $22.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Friday, April 16, 2021 - 2:30pm

Surgeons and patients visiting hospitals for various treatments are at increased risk of contracting COVID-19.

Key Points: 
  • Surgeons and patients visiting hospitals for various treatments are at increased risk of contracting COVID-19.
  • This has severely impacted healthcare revenue, as elective surgeries account for ~20% of the total healthcare revenue in countries such as the US.
  • This had a negative impact on the surgical devices market, including the laparoscopic instruments market, in 2020.\nBased on product, the global market is segmented into medical laparoscopic robots, energy devices, insufflators, suction/irrigation systems, laparoscopes, hand instruments, closure devices, access devices, and accessories.
  • Medical laparoscopic robots holds maximum share of the global laparoscopic instruments market in 2020.

Laparoscopic Instruments Market worth $22.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Friday, April 16, 2021 - 2:30pm

Surgeons and patients visiting hospitals for various treatments are at increased risk of contracting COVID-19.

Key Points: 
  • Surgeons and patients visiting hospitals for various treatments are at increased risk of contracting COVID-19.
  • This has severely impacted healthcare revenue, as elective surgeries account for ~20% of the total healthcare revenue in countries such as the US.
  • This had a negative impact on the surgical devices market, including the laparoscopic instruments market, in 2020.\nBased on product, the global market is segmented into medical laparoscopic robots, energy devices, insufflators, suction/irrigation systems, laparoscopes, hand instruments, closure devices, access devices, and accessories.
  • Medical laparoscopic robots holds maximum share of the global laparoscopic instruments market in 2020.

Olympus Opens New Global HQ for Therapeutic Solutions Division and U.S. Medical Business

Thursday, April 8, 2021 - 2:00am

Olympus opens global headquarters for Therapeutic Solutions and Medical Business in Westborough, MA, U.S.

Key Points: 
  • Olympus opens global headquarters for Therapeutic Solutions and Medical Business in Westborough, MA, U.S.
  • Since the Transform Olympus initiatives were unveiled in 2019, many U.S.-based executives have been leading TSD growth; Olympus has dramatically expanded the business with acquisitions, as well as through organic growth.
  • The facility will serve as one of several R&D hubs for Olympus, while enabling coordinated and agile management processes to support a global medical technology enterprise.
  • Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications.

Pristine Surgical and NexOptic Announce Commercial Agreement To Use AI for Single-Use Surgical Endoscopy Explains NexOptic Chairman Rich Geruson

Wednesday, April 7, 2021 - 2:15pm

Pristine Surgicals single-use endoscopes use high-performance digital image sensors, advanced high-brightness LEDs and powerful graphics-processing hardware and software to deliver high-definition, high-quality images in a single-use surgical endoscope at reduced cost.

Key Points: 
  • Pristine Surgicals single-use endoscopes use high-performance digital image sensors, advanced high-brightness LEDs and powerful graphics-processing hardware and software to deliver high-definition, high-quality images in a single-use surgical endoscope at reduced cost.
  • The companies will work together to incorporate NexOptics Aliis technology into Pristines single-use endoscopic visualization platform for image optimization.
  • Were excited to work with NexOptic to use theirALIIS platform to advance our deployment of artificial intelligence capabilities and help us further that mission.
  • Headquartered in Manchester, N.H., Pristine Surgical is led by an experienced management team, a seven-person board of managers and a 10-person medical advisory board.

Wyntrea L. Cunningham MD is recognized by Continental Who's Who

Tuesday, April 6, 2021 - 6:41pm

HOUSTON, April 6, 2021 /PRNewswire/ --Wyntrea L. Cunningham MD is being recognized by Continental Who's Who as a Top Obstetrics & Gynecology Specialist for her remarkable contributions in the medical field and her professional excellence at THC MediSpa and Clinic.

Key Points: 
  • HOUSTON, April 6, 2021 /PRNewswire/ --Wyntrea L. Cunningham MD is being recognized by Continental Who's Who as a Top Obstetrics & Gynecology Specialist for her remarkable contributions in the medical field and her professional excellence at THC MediSpa and Clinic.
  • At THC MediSpa & Clinic, primary provider Dr. Wyntrea L. Cunningham and her staff strive to deliver unparalleled service and solutions designed to meet each patient's unique needs.
  • In her current capacity, Dr. Cunningham performs invasive and minimally invasive surgery, including laparoscopic surgery.
  • Furthering her medical training, Dr. Cunningham completed her Obstetrics and Gynecology residency at the UT Houston McGovern Medical School.